Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Mazou Ngou Temgoua: Cancer and VTE – Toward Truly Personalized Anticoagulation
Mazou Ngou Temgoua/LinkedIn
Apr 23, 2026, 13:39

Mazou Ngou Temgoua: Cancer and VTE – Toward Truly Personalized Anticoagulation

Mazou Ngou Temgoua, Cardiology Intensive Care Physician at Châteauroux–Le Blanc Hospital Centre, shared a post on LinkedIn about recent article by Faizan Khan et al., published in European Heart Journal:

“Cancer and VTE: toward a truly personalized (and finally nuanced) anticoagulation

A major meta-analysis (>96,000 patients) provides a key message:

  • Not all cancers expose thrombosis vs bleeding to the same balance
  • And above all, the profiles are not symmetrical

What the study really shows: getting out of shortcuts

High thromboembolic risk (without necessarily increased bleeding) (e.g. pancreas, hepatobiliary, lung, history of VTE, ECOG >0)

  • Dominant pro-thrombotic profile

High bleeding risk (without clear evidence of reduced VTE risk) (e.g. gastrointestinal cancers [non-pancreas/hepatobiliary], brain, prostate, history of bleeding, ECOG ≥2)

  • Dominant haemorrhagic profile
  • But thrombotic risk is not necessarily low

High dual risk (critical profile) (e.g. cancers of the genitourinary tract, advanced cancer and deterioration of general condition)

  • High risk of recurrence and bleeding

Lower risk of recurrence (e.g. recent surgery, breast cancer)

  • More favourable profile
  • To be recontextualized according to tumor activity

Major implication: reasoning in terms of risk dominance (not simplistic categories)

Dominant thrombotic profile

  • Prolonged, intensive anticoagulation (greater than or equal to 6 months, no early reduction)

Dominant bleeding profile

  • Cautious, individualized anticoagulation
  • Not necessarily short, but adapted to the real context of VTE

High dual risk (the real challenge)

  • No standard solution
  • Tailor-made strategy:
  1. LMWH preferred
  2. Close reassessment
  3. Multidisciplinary discussion
  4. Shared decision-making

Lower risk profile (relative)

  • Standard anticoagulation
  • If active cancer, tendency to still prolong treatment (greater than or equal to 6 months)

What this study really changes

Breaks the simplistic opposition ‘high risk vs low risk’

Shows that some cancers are:

  • Purely thrombogenic (pancreas)
  • More haemorrhagic (digestive, brain)
  • Or mixed (genitourinary)

Bleeding risk does not equal protection against recurrence

Important limitations

Heterogeneity of studies

  • Combined factors not assessed
  • Absence of biomarkers
  • Current scores insufficient
  •  Uncertain applicability after the acute phase

Key message (essential takeaway)

  • The real advance is not to add risk factors
  • But to understand their interaction and clinical dominance

Anticoagulation in cancer becomes:

  • Dynamic
  • Personalized
  • Patient-centred

Future progress will require integrated models (clinical, biomarkers, and artificial intelligence) to manage these complex profiles.”

Title: Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis

Authors: Faizan Khan, Tobias Tritschler, Caterina E. Marx, Vincent Lanting, Bram Rochwerg, Alexandre Tran, Shannon M. Fernando, Diane L. Lorenzetti, Hannah Wunsch, Jessalyn Holodinsky, Kirsten Fiest, Henry Thomas Stelfox, Aurélien Delluc, Dean A. Fergusson, Grégoire Le Gal, Philip S. Wells, Tzu-Fei Wang, Kristen Sanfilippo, Nick van Es, Deborah Schrag, Jean M. Connors, Marc Carrier

Mazou Ngou Temgoua: Cancer and VTE - Toward Truly Personalized Anticoagulation

Stay updated with Hemostasis Today.

Alexandre Tran Aurélien Delluc Bram Rochwerg Caterina E. Marx Dean A. Fergusson Deborah Schrag Diane L. Lorenzetti Faizan Khan Gregoire Le Gal Hannah Wunsch Headlines Health Hematology Hemostasis Hemostasis News Hemostasis Today Henry Thomas Stelfox Jean M. Connors Jessalyn Holodinsky Kirsten Fiest Kristen Sanfilippo LMWH Marc Carrier Mazou Ngou Temgoua Medicine Nick van Es Philip S. Wells Shannon M. Fernando thrombosis Tobias Tritschler Tzu-Fei Wang Vincent Lanting
NewsFeed